David B. Weiner - Concepedia

Author

David B. Weiner

University of Pennsylvania ORCID

Also Known As

D B Weiner, D Makhatadze, D WEINER, D Weiner, D. B. Weiner, D. Weiner, D. weiner, D.B Weiner, D.B. WEINER, D.B. Weiner

798

Publications

32.6K

Citations

H-Index

213

Concepts

All Affiliations

University of Pennsylvania Inovio Pharmaceuticals (United States)The Wistar Institute University of South Florida Bioqual

About

David B. Weiner is an author at University of Pennsylvania specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	63	196	14.7K
2	Natural Sciences	14	16	997
3	Engineering	9	9	553
4	Public Health	4	4	906
5	Health Sciences	1	1	54

David B. Weiner

378

Publications

27.3K

Citations

H-Index

Page 1

	Year	Citations
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Erwei Song, Pengcheng Zhu, Sang‐Kyung Lee, Nature Biotechnology Cell-based Drug DeliveryCell-surface ReceptorsImmunoengineeringImmunologyCancer Vaccines	2005	1K
Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria Gregory F. Sonnenberg, Laurel A. Monticelli, Theresa Alenghat, Science	2012	712
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak, The Lancet ImmunologyHuman Papillomavirus 16Cancer-associated VirusCervical Cancer PreventionHuman Papillomavirus Vaccines	2015	689
Gene inoculation generates immune responses against human immunodeficiency virus type 1. B Wang, Kenneth E. Ugen, Vasantha Srikantan, Proceedings of the National Academy of Sciences ImmunologyGene InoculationImmune SystemImmunotherapyHuman Retrovirus	1993	653
First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response Rob Roy MacGregor, Jean Boyer, Kenneth E. Ugen, The Journal of Infectious Diseases	1998	638
Immunogenicity of a DNA vaccine candidate for COVID-19 Trevor R.F. Smith, Ami Patel, Stephanie Ramos, Nature Communications	2020	635
p185neu expression in human lung adenocarcinomas predicts shortened survival. Jeffrey A. Kern, David A. Schwartz, Joanne E. Nordberg, PubMed Human CarcinogenesisOncologyLung InflammationMedicinePathology	1990	436
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation David B. Weiner, Jing Liu, Jeffrey A. Cohen, Nature Signal TransductionNeu Oncogene MimicsG Protein-coupled ReceptorFunctional SelectivityReceptor (Biochemistry)	1989	427
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination Jean Boyer, Kenneth E. Ugen, Bin Wang, Nature Medicine VaccinationVaccine DevelopmentDna VaccinationHuman RetrovirusImmunology	1997	355
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial Kayvon Modjarrad, Christine C. Roberts, Kristin T Mills, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2019	314

Page 1